杜立在演讲中指出，中国与美国的医疗环境和政策差距巨大，因此在发展生物制药的策略上应充分考虑自身国情。他认为，就整个医疗系统而言，医疗改革对创新生物制药研发的影响尤为显著，由于生物制药在国内定价偏低，许多初创团队在药物临床试验阶段将药物出售给国外公司， ...

记者安格斯‧赫维（Angus Hervey）说，你是否相信世界末日可能取决于你从哪里获得新闻。他讲述了主流媒体机构去年错过的进展——从清洁能源的进步到极端贫困率、犯罪率和疾病率的下降——并建议我们应该更多地关注此类事件。赫维说：“如果我们希望更多的人致力于取得进步，那么也许我们应该告诉更多的人取得进步是可能的。” ...

It’s been almost a year since the Food and Drug Administration approved the first genetic treatments for sickle cell disease.

β-Thalassemia is a genetic disorder characterized by reduced or absent synthesis of the beta chains of hemoglobin, leading to ineffective erythropoiesis and severe anemia. Patients with ...

The first therapy that uses gene-editing is to be offered on the NHS in a “revolutionary breakthrough” for patients. It will ...

This investor is excited about the transformational potential of one growth stock that he's been eyeing up for his portfolio.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

For those with $200 to spare that isn't being saved for emergencies, let's consider two healthcare stocks within that budget ...

Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $29.9 billion by 2032, ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Three senior figures at the US National Institutes of Health explain why the agency remains committed to supporting basic science and research.